2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 1609

Lack of Association Between ZHX2, Lepr, Gckr and ASCL1 and Carotid Intima-Media Thickness, Carotid Plaques and Cardiovascular Disease in Patients with Rheumatoid Arthritis
Abstract Number: 1952

Lack of Association of a 6.7 Kbp Deletion of LILRA3 with Giant Cell Arteritis
Abstract Number: 1659

Lack of Effect of Reduced Folic Acid Supplementation on Disease Activity in RA
Abstract Number: 1615

Lack of Replication of the Association Between Anti-Citrullinated Fibrinogen and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Abstract Number: 336

Lack of Uniform Diagnostic Criteria for Erosive OA: A Systematic Review
Abstract Number: 1991

Large Vessel Involvement By IgG4-Related Disease
Abstract Number: 2979

Laser Speckled Imaging and Videomicroscopy Assessment of Sublingual Perfusion in Systemic Sclerosis and Healthy Controls
Abstract Number: 733

Late Onset Systemic Lupus Erythematosus: A Different Disease Subset?
Abstract Number: 894

Late-Onset IgA Vasculitis in Adult Patients Exhibits Distinct Clinical Characteristics and Outcomes
Abstract Number: 2903

Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Abstract Number: 2790

Leflunomide/Hydroxychoroquine Combination Treatment Additively Inhibits T Cell Receptor/Toll-like Receptor 9-Triggered Th1 and Th17 Cytokine Secretion
Abstract Number: 1821

Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study
Abstract Number: 2353

Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Abstract Number: 2113

Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Abstract Number: 2596

Less Musculoskeletal Ultrasound Power Doppler Activity Seen in Obese Rheumatoid Arthritis
Abstract Number: 1085

Levamisole Triggers Neutrophil Extracellular Trap Formation through Muscarinic Receptors in Patients with Drug-Induced Vasculitis
Abstract Number: 334

Lifetime Risk of Symptomatic Hand Osteoarthritis: The Johnston County Osteoarthritis Project
Abstract Number: 135

Limitations of Treat-to-Target in Rheumatoid Arthritis: Joint Damage Appears As Severe As Inflammation in Contemporary Care at One Site
Abstract Number: 1508

Lipid Target Achievement Among Patients with Recent-Onset Rheumatoid Arthritis during the First Six Years of Follow-up: Results from a French Multicenter Cohort of Early Arthritis
Abstract Number: 1788

Lipoprotein Subfractions and Cardiovascular Disease in Systemic Lupus Erythematosus
Abstract Number: 2336

Literature Review of Patient Reported Outcome and Health Related Quality of Life Measures for Biologic Therapies in the Management of Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 2152

Long Noncoding H19X Is a Key Mediator of Tgf-Beta Induced Pro-Fibrotic Effects in the Pathogenesis of Systemic Sclerosis and Other Fibrotic Diseases
Abstract Number: 3041

Long Term Biological Therapy in Uveitis Refractory Due to Behçet’s Disease. Multicenter Study of 165 Patients.
Abstract Number: 2049

Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases
Abstract Number: 406

Long Term Follow up of Inner City Pediatric Patients with Lupus Nephritis
Abstract Number: 3069

Long Term Follow-up Results of Endovascular Repair in the Management of Arterial Stenosis Caused By Takayasu Arteritis
Abstract Number: 1396

Long Term Outcome of Neurosarcoidosis
Abstract Number: 2195

Long Term Outcome of Primary Antiphospholipid Syndrome Patients: A Multicenter Study
Abstract Number: 1701

Long Term Outcome of Total Hip Replacement in Patients with Ankylosing Spondylitis
Abstract Number: 2840

Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Abstract Number: 2843

Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
Abstract Number: 619

Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Abstract Number: 1446

Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
Abstract Number: 2885

Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study
Abstract Number: 939

Long-Term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome
Abstract Number: 938

Long-Term Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF Receptor-Associated Periodic Syndrome
Abstract Number: 2427

Long-Term Efficacy and Safety of Mycophenolate Mofetil in Childhood Primary Central Nervous System Vasculitis
Abstract Number: 1351

Long-Term Efficacy of Latent Tuberculosis Infection Screening in Juvenile Idiopathic Arthritis Patients Prior to Anti-TNF Treatment in an Endemic Area
Abstract Number: 596

Long-Term High Remission Rates and Distinct Trajectories of Disease Activity Following the Implementation of Treat-to-Target in Early Rheumatoid Arthritis
Abstract Number: 2835

Long-Term Improvements with Certolizumab Pegol in Joints and Extra-Articular Manifestations of Psoriatic Arthritis in Patients with and without Prior Anti-TNF Exposure
Abstract Number: 276

Long-Term Outcome in Mixed Connective Tissue Disease
Abstract Number: 1816

Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis
Abstract Number: 2046

Long-Term Outcomes in Cardiac Neonatal Lupus and Associated Risk Factors for Morbidity
Abstract Number: 404

Long-Term Outcomes of Macrophage Activation Syndrome in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 780

Long-Term Prognosis and Factors Associated with Damage Accrual in Japanese Patients with Systemic Lupus Erythematosus
Abstract Number: 1633

Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months
Abstract Number: 2765

Long-Term Retention Rate of First Biologics in Patients of Age over 75 Years with Rheumatoid Arthritis in Japanese Clinical Practice: Results from the Multicenter Biologic Registry
Abstract Number: 3111

Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 1649

Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment
Abstract Number: 1795

Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Abstract Number: 2431

Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis
Abstract Number: 2759

Long-Term Survival of Biological Therapy in Rheumatoid Arthritis Elderly Patients in Clinical Practice
Abstract Number: 1977

Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Abstract Number: 2854

Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study
Abstract Number: 1225

Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Abstract Number: 891

Long-Term Use of Rituximab for Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 2864

Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies
Abstract Number: 2942

Longitudinal Analyses of Progression of Brain Athrophy in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2978

Longitudinal Assessment of Gastrointestinal Symptoms in the Prospective Registry of Early Systemic Sclerosis Cohort
Abstract Number: 744

Longitudinal Assessment of Th1 and Th2 Cytokines: A Comparison Between Adult-Onset and Childhood-Onset Systemic Lupus Erythematous
Abstract Number: 397

Longitudinal Observation of Psychological Factors and Health-Related Quality of Life in Childhood-Onset Lupus
Abstract Number: 113

Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study
Abstract Number: 2524

Longterm Follow-up of Children Born to Mothers with Chronic Arthritides and Exposed to Anti-TNF Alfa Agents during Pregancy and Breastfeeding: A Case-Control Study
Abstract Number: 2774

Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Abstract Number: 2203

Loss of Wdfy3 Leads to Enhanced Osteoclastogenesis Via NF-κB Activation
Abstract Number: 352

Low Bone Density Is Associated with Atherosclerotic Disease in Patients with Psoriatic Arthritis
Abstract Number: 2068

Low Complement Is Associated with SLE Classification Criteria and Organ Damage
Abstract Number: 446

Low Disease Activity at 12 Weeks and 24 Weeks Is Predictive of Normalized Health-Related Quality of Life in Methotrexate-Experienced Patients with Active Rheumatoid Arthritis Treated with Intravenous Golimumab Plus Methotrexate
Abstract Number: 2658

Low Disease Activity Is Associated with Higher HDL and a Trend to Lower Insulin Resistance in Rheumatoid Arthritis Patients
Abstract Number: 2169

Low Education Is Associated with Mortality Among Individuals with Knee and/or Hip OA: The Johnston County Osteoarthritis Project
Abstract Number: 1137

Low Molecular Weight Polyphenol Harpagoside Inhibits IL-1β-Induced Expression of IL-6 By Blocking the Expression and Activity of c-Fos in Primary Human Osteoarthritis Chondrocytes
Abstract Number: 2933

Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse
Abstract Number: 1270

Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study
Abstract Number: 85

Low Socioeconomic Status, High Disability Rates, and Increased Use of Health Care Resources in Fibromyalgia Patients Taking Narcotics
Abstract Number: 882

Lung Damage in ANCA Associated Vasculitis Assessed By Vasculitis Damage Index: Recurrent Pulmonary Infections Have a Significant Contribution
Abstract Number: 814

Lupus Drives Atherosclerosis through CD4+CXCR3+ T Cells and Plasmacytoid Dendritic Cells
Abstract Number: 2921

Lupus Nephritis: An Exploration of Management Style
Abstract Number: 763

Lupus-Related SNPs and Risk of Diffuse Large B-Cell Non-Hodgkin Lymphoma
Abstract Number: 1777

Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
Abstract Number: 869

Lymphoma in Patients with Granulomatosis with Polyangiitis
Abstract Number: 2052

Lymphoma in Patients with Rheumatoid Arthritis Treated with Biologic Drugs: Long-Term Follow-up of Risks and Lymphoma Subtypes
Abstract Number: 815

Lys63-Polyubiquitination By the E3 Ligase Casitas B-Lineage Lymphoma-b Modulates Peripheral Regulatory T Cell Tolerance in Patients with Systemic Lupus Erythematosus
Abstract Number: 1913

Lysyl Oxidase Induces Fibrosis Via Upregulation of IL-6 and Serves As a Biomarker to Monitor Response to Therapy

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].